Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53 Gene Therapy for Diabetes Concurrent with HCC
NCT02561546Phase 2Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAdp53 in hepatocellular carcinoma (HCC), diabetes mellitus (DM), sponsored by Shenzhen SiBiono GeneTech. Status: unknown.
02
Drugs
rAdp53
03
Conditions
hepatocellular carcinoma (HCC)diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02561546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561546.